Related Experiment Video
Updated: Jul 4, 2026
Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
Published on: December 1, 2023
Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity
Z Sternberg1, B Weinstock-Guttman, D Hojnacki
1Department of Neurology, Baird MS Center, Jacobs Neurological Institute, Buffalo, NY 14203, USA. zs2@buffalo.edu
Objectives:
To compare serum levels of the receptor for advanced glycation end products (sRAGE) between multiple sclerosis (MS) patients and healthy control subjects, and to investigate whether serum sRAGE levels correlate with MS disease severity as indicated by the Kurtzke Expanded Disability Status Scale (EDSS).
Method:
37 patients with clinical diagnosis of MS and 22 healthy control subjects were investigated in a cross-sectional study using enzyme-linked immunosorbent assays (ELISA).
Results:
Serum levels of sRAGE were found to be significantly lower in MS patients compared to levels in healthy controls (p = 0.005). A trend toward lower levels of serum sRAGE was observed in female MS patients compared to their male counterparts (p = 0.05). A relationship between sRAGE and EDSS, and sRAGE and rate of clinical relapse was observed (p = 0.012).
Conclusion:
The significant reduction of sRAGE in MS patients relative to healthy controls supports the potential role for RAGE axis in MS clinical pathology. Lower levels of sRAGE may be associated with enhanced inflammatory responses. Based on these observations, further investigations into the role of sRAGE in MS clinical pathology is warranted.
Insights
Serum levels of the receptor for advanced glycation end products (sRAGE) were significantly lower in multiple sclerosis (MS) patients compared to controls. Lower sRAGE may indicate increased inflammation in MS.
Area of Science:
- Neuroimmunology
- Biomarkers in Neurological Diseases
Background:
- The receptor for advanced glycation end products (RAGE) pathway is implicated in inflammatory and neurodegenerative processes.
- Understanding the role of soluble RAGE (sRAGE) in multiple sclerosis (MS) pathogenesis is crucial for developing targeted therapies.
Purpose of the Study:
- To compare serum sRAGE levels between MS patients and healthy controls.
- To investigate the correlation between serum sRAGE levels and MS disease severity, including disability (EDSS) and relapse rate.
Main Methods:
- A cross-sectional study involving 37 MS patients and 22 healthy controls.
- Serum sRAGE levels were quantified using enzyme-linked immunosorbent assays (ELISA).
Main Results:
- MS patients exhibited significantly lower serum sRAGE levels than healthy controls (p = 0.005).
- A trend towards lower sRAGE was noted in female MS patients versus males (p = 0.05).
- Serum sRAGE levels correlated with MS disease severity (EDSS) and clinical relapse rate (p = 0.012).
Conclusions:
- Reduced serum sRAGE in MS patients suggests a role for the RAGE axis in disease pathology.
- Lower sRAGE levels may be linked to heightened inflammatory responses in MS.
- Further research is warranted to elucidate the specific role of sRAGE in MS pathogenesis and its potential as a therapeutic target.
